Info
"Tracing papers" : a comparison of COVID-19 data privacy bills / / Jonathan M. Gaffney
| "Tracing papers" : a comparison of COVID-19 data privacy bills / / Jonathan M. Gaffney |
| Autore | Gaffney Jonathan M. |
| Edizione | [[Library of Congress public edition].] |
| Pubbl/distr/stampa | Washington, District of Columbia : , : Congressional Research Service, , 2020 |
| Descrizione fisica | 1 online resource (5 pages) |
| Disciplina | 614.592414 |
| Collana | Legal sidebar |
| Soggetto topico | COVID-19 (Disease) |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti |
"Tracing papers"
Tracing Papers |
| Record Nr. | UNINA-9910717381003321 |
Gaffney Jonathan M.
|
||
| Washington, District of Columbia : , : Congressional Research Service, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in data science and intelligent data communication technologies for COVID-19 : innovative solutions against COVID-19 / / Aboul Ella Hassanien, Sally M. Elghamrawy and Ivan Zelinka (editors)
| Advances in data science and intelligent data communication technologies for COVID-19 : innovative solutions against COVID-19 / / Aboul Ella Hassanien, Sally M. Elghamrawy and Ivan Zelinka (editors) |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (311 pages) |
| Disciplina | 614.592414 |
| Collana | Studies in Systems, Decision and Control |
| Soggetto topico |
Engineering - Data processing
Computational intelligence Big data |
| ISBN | 3-030-77302-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910522988503321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Alternative medicine interventions for COVID-19 / / Muhammad Zia-Ul-Haq [and three others] editors
| Alternative medicine interventions for COVID-19 / / Muhammad Zia-Ul-Haq [and three others] editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (291 pages) |
| Disciplina | 614.592414 |
| Soggetto topico |
COVID-19 (Disease) - Alternative treatment
COVID-19 Medicina alternativa |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-67989-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- About the Editors -- Chapter 1: Introduction to COVID-19 -- Introduction -- Origin of COVID -- Emergence and Epidemiology -- Human-Animal Interaction as Risk Factor -- Best Suitable Animal Model -- COVID and Animal Welfare -- Molecular Differences Between Different Animal Species -- Vaccines for COVID from Animals -- Conclusion -- References -- Chapter 2: Medicinal Plants as COVID-19 Remedy -- Introduction -- Existing Plants with Potential Therapeutic Applications for Coronavirus Family (SARS-CoV) -- Plants as Specific Inhibitors of HCoV Target Proteins -- Bupleurum Species -- Artemisia annua L. -- Isatis indigotica Fortune ex Lindl. -- Alcea digitata (Boiss.) Alef. -- Lycoris radiata (L'Hér.) Herb. -- Pyrrosia lingua (Thunb.) Farw. -- Houttuynia cordata Thunb. -- Torreya nucifera L. -- Lindera aggregata (Sims) Kosterm. -- Rheum palmatum L. -- Cerasus avium (L.) Moench. -- Polygonum multiflorum Thunb. -- Citrus aurantium L. -- Rubia tinctorum L. -- Onopordum acanthium L. -- Quercus infectoria G. Olivier -- Crataegus microphylla C. Koch -- Berberis integerrima Bunge -- Alnus japonica (Thunb.) Steud. -- Paulownia tomentosa (Thunb.) Steud. -- Psoralea corylifolia L. -- Tribulus terrestris L. -- Medicinal Plants as Potential Source of Natural Antiviral Agents Against COVID -19 -- Allium Sativum (Garlic) -- Azadirachta indica (Neem) -- Curcuma domestica (Turmeric, Haldi) -- Echinacea purpurea L. (Echinacea) -- Foeniculum vulgare Mill. (Fennel) -- Glycyrrhiza glabra (Licorice) -- Melissa officinalis L. (Lemon Balm) -- Mentha piperita L. (Peppermint) -- Nigella sativa L. (Black Seeds) -- Origanum vulgare L. (Oregano) -- Ocimum bacilicum L. (Basil) -- Rosmarinus officinalis L. (Rosemary) -- Salvia officinalis L. (Sage) -- Senna alexandrina Mill. (Senna Makki) -- Zingiber officinale Rosc. (Ginger) -- Limitations.
Conclusions -- References -- Chapter 3: Traditional Chinese Medicines as Possible Remedy Against SARS-CoV-2 -- Introduction -- Traditional Chinese Medical Practices -- Laws for TCM Formulation -- Antiviral Potential of Plant Metabolites -- Structure of SARS-CoV-2 -- Relevance of SARS-CoV with SARS-CoV-2 -- Entry of SARS-CoV vs. SARS-CoV-2 into Host Cell -- TCM and SARS-CoV -- TCM and SARS-CoV-2 (COVID-19) -- Most Practiced Herbs in Formulations Against COVID-19 -- Utilization Frequency of Herbs in the Formulation of (COVID-19) Decoctions -- Approved/Proposed Decoctions with Successful Clinical Trials -- Qingfei Paidu Decoction (QFPD) (Approved) -- Huashi Baidu Decoction (HBD) (Approved) -- Xiaochaihu Decoction (XCHD) -- Xuanfei Baidu Decoction (XFBD) (Approved) -- Jinhua Qinggan (JQ) (Approved) -- Huoxiang Zhengqi (HZ) Capsule -- Lianhua Qingwen (LQ) -- Xuebijing Injection (XbI) (Approved) -- Reduning Injection (RdI) -- Shufeng Jiedu Capsule (SFJC) -- Ma Xing Shi Gan Decoction (MXSGD) (Approved) -- Yin Qiao San (YQS) -- Yupingfeng San (YPFS) -- Therapeutic Logic of TCM as COVID-19 Inhibitor -- Mechanism of Direct Inhibition -- TCM Targeting ACE2 -- TCM Targeting Protease -- TCM Directly Targeting DNA Via Intercalation -- TCM Directly Targeting DNA via JAK-STAT Signaling Pathway -- TCM Targeting sEH -- Targeting VEGF -- Targeting DPP4 -- Targeting JUN -- Targeting EGFR -- Targeting IL1B -- Mechanism of Indirect Mechanisms -- Anti-inflammation and Immune Regulation to Avoid Cytokine Storm -- TCM Protect Organ Damage in COVID-19 Patients -- Regulation of Renin-Angiotensin-Aldosterone System (RAAS) and Potential TCM Targets -- Cytokine-Mediated Positive and Negative Immunity -- TCM Targeting MAPK (Cytokine) -- TCM Targeting Platinum Drug Resistance (Cytokine) -- TCM Targeting Tyrosine Kinase Resistance (Cytokine). TCM Targeting Interleukins (ILs) (Cytokine) -- TCM Targeting TNF (Cytokines) -- TCM Targeting Lymphocyte-Mediated Adaptive Immune System -- Regulation of Apoptosis and Potential TCM Targets -- TCM Targeting BCL Proteins -- TCM Targeting CASP -- 7TCM Targeting Akt or Protein Kinase B (PKB) -- Regulation of NF-κB Pathway and Potential TCM Targets -- TCM Targeting TP53 -- TCM Targeting ICAM1 -- TCM Targeting RELA -- Regulation of Arachidonic Acid Metabolism and Potential TCM Targets -- TCM Targeting cPLA2α of Arachidonic Acid Metabolism -- TCM Targeting Cyclooxygenase-2 of Arachidonic Acid Metabolism -- TCM Targeting LOX of Arachidonic Acid Metabolism -- TCM Targeting Cytochrome P450 -- TCM Targeting Leukotrienes (LTs) -- TCM Targeting CALM -- TCM Targeting HIF-1 Signaling Pathways -- TCM Targeting Endocrine Resistance -- TCM Targeting FOS -- TCM Targeting PTGS2 -- Regulation of Polyamine Metabolism and Potential TCM Targets -- TCM Targeting NOS2 and AOC1 -- TCM Targeting CCL2 -- Meta-analysis -- TCM from Chinese Combat Zone to World Combat Zone -- Shortcomings of Antiviral Medicine on COVID-19 -- Conclusions -- References -- Chapter 4: Plant-Based Natural Products: Potential Anti-COVID-19 Agents -- Introduction -- Antiviral Mechanistic Aspects of Phytochemicals -- Mechanism -- Plant Selection for Antiviral Screening -- Different Classes of Phytochemicals as Antiviral Agents -- Alkaloids -- Flavonoids -- Classification of Flavonoids -- Chalcones -- Dihydrochalcones -- Flavones -- Flavonones -- Dihydroflavonols -- Flavonol -- Isoflavonoids -- Isoflavones -- Isoflavanones -- Neoflavonoids -- Terpenoids -- Tannins -- Vitamins -- Chromones and Coumarins -- Organosulfur Compounds -- Selenium Compounds -- Miscellaneous Antiviral Phytochemicals -- Curcumin and Its Derivative -- Chlorophyllin -- Gingerols -- Chitin and Chitosan -- Anthraquinone -- Conclusion. References -- Chapter 5: Foods as First Defense Against COVID-19 -- Introduction -- Role of Nutrition and Diet in Prevention and Management of COVID-19 -- Prioritizing Nutrition Interventions During COVID-19 -- Grains -- Vegetables and Fruits -- Nuts -- Legumes -- Meat -- Milk and Milk Products -- Herbs -- Role of Vitamins in COVID-19 -- Vitamin A -- Vitamin B -- Vitamin C -- Vitamin D -- Vitamin E -- Role of Minerals in COVID-19 -- Iron -- Selenium -- Zinc -- Magnesium -- Role of Omega-3 Polyunsaturated Fatty Acids -- Nutrients for Immune System and Resilience in COVID-19 -- Nutrition in Lowering Stress and Depression in COVID-19 -- Food Choices for Diabetic Patients During COVID-19 -- Food Choices for Cardiovascular Patients During COVID-19 -- Food Choices for Cancer Patients During COVID-19 -- Food Choices for Patients with Digestive Disorders During COVID-19 -- Food Choices for Pulmonary Disease Patients During COVID-19 -- Malnutrition May Exacerbate COVID-19 -- Nutrition and Post-COVID Recovery -- Future Perspectives -- Conclusion -- References -- Chapter 6: Drugs for the Treatment of COVID-19 -- Introduction -- Dexamethasone -- Chloroquine -- Remdesivir -- Angiotensin-Converting Enzyme Inhibitors -- Spike Protein Inhibitors -- Conclusions -- References -- Chapter 7: COVID-19 Pandemic and Vaccines -- Introduction -- COVID-19 Vaccines: A Need of Time -- Coronavirus Vaccine Development: Challenges of the Past -- Vaccine Development Strategies -- Nucleic Acid Vaccines -- Protein Subunit Vaccines -- Inactivated or Live-Attenuated Virus Vaccines -- Virus Vector-Based Vaccines -- Repurposed Vaccines for COVID-19 and Off-Target Effects of Other Vaccines -- Plant-Based Vaccines -- Animal Models for SARS-CoV-2 Studies -- Cell Culture Systems for SARS-CoV-2 Studies -- Clinical and Immunological Endpoints -- Vaccine Development Landscape. Global and Equitable Distribution of Vaccines -- Vaccine Developers and Geographical Distribution -- Conclusions -- References -- Chapter 8: Updates in Vaccine Development Against COVID-19 -- Introduction -- Sinovac Biotech, China -- Conclusions -- Bibliography -- Chapter 9: COVID-19: Recent Developments in Therapeutic Approaches -- Introduction -- Morphology of SARS-CoV-2 -- Genome Organization of SARS-CoV-2 -- Replication of SARS-CoV-2 -- Transmission and Pathogenesis of SARS-CoV-2 -- Clinical Characterization of SARS-CoV-2 -- Clinical and Laboratory Diagnosis of SARS-CoV-2 -- Therapeutic Options for the Treatment of COVID-19 -- Antivirals or Immunomodulatory Drugs for COVID-19 -- Vaccine for COVID-19 -- Plasma/Serotherapy for COVID-19 -- Alternative Therapies -- Anticoagulant Therapy -- Glucocorticoids (GC) -- Stem Cell-Based Therapy -- ACE-2-Mediated Therapies -- CRISPR/Cas System -- Conclusion -- References -- Index. |
| Record Nr. | UNINA-9910483536303321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Because COVID ... : Pandemic Responses, Rationales and Ruses
| Because COVID ... : Pandemic Responses, Rationales and Ruses |
| Autore | Leitch Shirley <1960-> |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Canberra : , : ANU Press, , 2025 |
| Descrizione fisica | 1 online resource (256 pages) |
| Disciplina | 614.592414 |
| Altri autori (Persone) | WheelerSally |
| Collana | Australia and the World Series |
| Soggetto topico |
Coronaviruses
COVID-19 (Disease) - Economic aspects - Australia |
| ISBN |
9781760466923
1760466921 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. The Australian pandemic experience / Shirley Leitch and Sally Wheeler -- 2. History, the pandemic and the future / Frank Bongiorno -- 3. Public value science outcomes: Lessons from the COVID-19 pandemic / Barry Bozeman -- 4. JobKeeper: A critical analysis / Rohan Pitchford and Rabee Tourky -- 5. Bioethics after COVID-19: Should we embrace a political turn? / Nathan Emmerich -- 6. The disruption of consumption / Sally Wheeler -- 7. The arts, music and the pandemic / Kim Cunio -- 8. 'Ten footies, one small saltie': The Northern Territory experience and the shadow pandemic / Chay Brown -- 9. The impact of News Corporation scepticism on the COVID-19 pandemic: A case study from Victoria, June-August 2020 / Tony Ward -- 10. Australia and forced displacement: A new research agenda? / Kate Ogg -- CONCLUSIONS 11. Pandemic daze: From causal to casual / Mark Kenny -- 12. Proactive mitigation responses to COVID pandemics: Learning lessons needed to achieve a compassionate, resilient future / Robert L. Heath -- 13. Afterword / Shirley Leitch and Sally Wheeler. |
| Record Nr. | UNINA-9911011370803321 |
|
Leitch Shirley <1960->
|
||
| Canberra : , : ANU Press, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cardiovascular complications of COVID-19 : risk, pathogenesis and outcomes / / Umair Mallick
| Cardiovascular complications of COVID-19 : risk, pathogenesis and outcomes / / Umair Mallick |
| Autore | Mallick Umair |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (416 pages) |
| Disciplina | 614.592414 |
| Soggetto topico |
COVID-19 (Disease)
Cardiovascular system - Diseases |
| ISBN |
9783030900656
9783030900649 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- 1 The Epidemiology of CoViD19 and Cardiovascular Diseases -- 1.1 Introduction -- 1.2 Epidemiology -- 1.2.1 Cardiovascular Disease or CoViD19, Which Comes First? -- 1.2.2 The Burden of Cardiovascular Risk Factors in CoViD19 -- 1.2.3 Role of the Pre-existing Cardiovascular Diseases in CoViD19 -- 1.2.4 Critical CoViD19 Complications and Pre-existing Cardiovascular Disease -- 1.2.5 Role of Cardiovascular Complications in CoViD19 Mortality -- 1.3 Discussion -- 1.4 Conclusion -- References -- 2 Virology of CoViD19 -- 2.1 Viral Characteristics -- 2.1.1 Origins of SARS CoV2 -- 2.1.2 Hosts -- 2.1.3 SARS CoV2 Structure -- 2.1.4 SARS CoV2 Affinity and Infectivity -- 2.1.5 SARS CoV2 Variability and Strains -- 2.2 Mechanism of Viral Entry in Cells -- 2.2.1 SARS CoV2 Viral Spike-ACE2 Signaling Mechanisms -- 2.2.2 SARS COV, Cell Entry, and Receptors -- 2.2.3 SARS CoV2 Similarities with SARS COV and MERS -- 2.2.4 SARS CoV2, Cell Entry and Receptors -- 2.3 Summary -- References -- 3 An Introduction to the Clinical and Diagnostic Features, and CoViD19 Complications -- 3.1 Introduction -- 3.2 Clinical Symptomatology -- 3.3 Sepsis and Complications of CoViD19 -- 3.4 Important Diagnostic Features -- 3.4.1 Viral Sampling -- 3.4.2 Biochemical and Hematological Features -- 3.4.3 Radiological Features -- 3.5 Summary -- References -- 4 The Pathological Features of CoViD19 Cardiovascular Complications -- 4.1 Introduction -- 4.2 Key Features of Cardiovascular Pathology -- 4.2.1 The Myocardial Injury in CoViD19 -- 4.2.2 Endomyocardial Biopsy and Myocarditis -- 4.2.3 Endomyocardial Biopsy and Myocarditis with Viral Localization -- 4.2.4 The Vascular Injury, Microvascular Cardiac Involvement, and Thromboembolic Features -- 4.2.5 Endothelial Cell Infection and Apoptosis -- 4.3 Summary -- References -- 5 Treatment Options in CoViD19 -- 5.1 Introduction.
5.2 Antiviral Agents in CoViD19 -- 5.2.1 Viral Cell Entry Inhibition and Viral Assembly Blockage -- 5.3 Amino Quinolones in CoViD19 -- 5.3.1 Analysis of Body of Evidence on Amino Quinolones in CoViD19 -- 5.4 Immune-Based Therapies in CoViD19 -- 5.4.1 Immunomodulatory Agents -- 5.4.2 Convalescent Plasma, and Antibody-Based Therapies -- 5.5 Potential Anti-inflammatory Mechanisms -- 5.5.1 NOD-Like Receptor Protein 3 (NLRP3)-Anti-inflammasomes -- 5.5.2 Neutrophil Extracellular Traps (NETs)-Anti NETosis Therapy -- 5.6 Anticoagulants -- 5.7 CoViD19 Vaccines -- 5.8 Summary -- References -- 6 An Introduction to the Pathogenetic Mechanisms of CoViD19 Complications -- 6.1 Introduction -- 6.2 Acute Pulmonary Injury -- 6.3 Sepsis and Multi-organ Failure -- 6.4 Renin Angiotensin System -- 6.5 Endothelin System -- 6.6 Immune-Inflammation -- 6.7 Summary -- References -- 7 Overview of Cytokines and CoViD19 -- 7.1 Introduction -- 7.2 Cytokines -- 7.2.1 Interferon -- 7.2.2 Interleukins -- 7.2.3 Chemokines -- 7.2.4 Colony Stimulating Factors -- 7.2.5 Tumor Necrosis Factor -- 7.3 Cytokine Storm in CoViD19 -- 7.3.1 Kinetics of the Cytokine Storm -- 7.3.2 The "T" Cell Response -- 7.3.3 Cytokines and Severity of CoViD19 -- 7.4 Cytokines in Cardiovascular and Metabolic Diseases -- 7.5 Summary -- References -- 8 The Renin-Angiotensin System in COVID19 -- 8.1 Introduction -- 8.2 The Renin Angiotensin System -- 8.2.1 ACE2 Synthesis and Distribution -- 8.2.2 ACE2 Expression -- 8.2.3 ACE2 Detection -- 8.3 The Dynamics of ACE2 Expression in CoViD19 -- 8.3.1 ACE2 Expression in Cardiovascular and Metabolic Conditions -- 8.3.2 The Dynamics of ACE2 Expression and Cardiovascular Risk in CoViD19 -- 8.3.3 Age and Gender Variations of ACE2 and CoViD19 -- 8.4 ACE2 is a Marker of Severity or a Compensatory Mechanism? -- 8.5 Summary -- References -- 9 Thrombosis in CoViD19. 9.1 Epidemiology -- 9.2 Mechanisms Promoting Thrombosis in CoViD19 -- 9.2.1 Renin Angiotensin System and Thrombosis -- 9.2.2 Endothelial Cell Damage and Thrombosis -- 9.2.3 Inflammation and Thrombosis -- 9.2.4 Microangiopathy and Thrombosis in CoViD19 -- 9.2.5 Platelets and Thrombosis in CoViD19 -- 9.2.6 D Dimers in CoViD19 -- 9.2.7 Hypoxia and Thrombosis -- 9.2.8 Ethnic Disparities, High-Risk Subgroups and Coagulation -- 9.3 Summary -- References -- 10 Pathogenesis of CoViD19-Miscellaneous Mechanisms -- 10.1 Introduction -- 10.2 Regulatory Peptide Systems in CoViD19 -- 10.2.1 Kallikrein-Kinin System -- 10.2.2 Endothelin System -- 10.2.3 Natriuretic Peptide System -- 10.3 Miscellaneous Mechanisms -- 10.3.1 Direct Viral Damage -- 10.3.2 Endoplasmic Reticulum Stress -- 10.3.3 Cell Death Modalities -- 10.3.4 Mitochondrial Dysfunction -- 10.4 Summary -- References -- 11 Myocardial Injury in CoViD19 -- 11.1 Introduction -- 11.2 Epidemiology of Myocardial Injury -- 11.3 Definition, Presentation, and Challenges of Myocardial Injury -- 11.4 Timing and Assessment of Myocardial Injury -- 11.5 Biomarkers of Myocardial Injury -- 11.6 Pathogenesis of the Myocardial Injury -- 11.7 Summary -- References -- 12 Heart Failure in CoViD19 -- 12.1 Epidemiology -- 12.2 Role of Comorbidities in Heart Failure with CoViD19 -- 12.3 Biomarkers of Heart Failure in CoViD19 -- 12.4 Pathogenetic Mechanisms of Heart Failure in CoViD19 -- 12.5 Summary -- References -- 13 Hypertension in CoViD19 -- 13.1 Epidemiology -- 13.2 Complexities in Hypertension and CoViD19 -- 13.3 CoViD19 Susceptibility and Hypertension -- 13.4 Pathogenesis -- 13.5 Summary -- References -- 14 Cardiac Arrhythmias in CoViD19 -- 14.1 Epidemiology of Arrhythmias in CoViD19 -- 14.2 Pathogenesis of Arrhythmias in CoViD19 -- 14.3 Summary -- References -- 15 Acute Coronary Syndromes in CoViD19. 15.1 Epidemiology of Acute Coronary Syndromes in CoViD19 -- 15.2 Defining Acute Coronary Syndromes, Challenges in Presentation and Assessment -- 15.3 Pathogenesis of Acute Coronary Syndromes in CoViD19 -- 15.4 Summary -- References -- 16 Diabetes Mellitus and COVID19 -- 16.1 Epidemiology -- 16.2 Pathogenesis -- 16.3 Treatment Implications -- 16.4 Summary -- References -- 17 Obesity and COVID19 -- 17.1 Introduction -- 17.2 Pathogenetic Links - Obesity and CoViD19 -- 17.3 Summary -- References -- 18 The Older Age Adults and COVID19 -- 18.1 Epidemiology -- 18.1.1 Oder Age and CoViD19 Criticality -- 18.1.2 CoViD19 Fatality in Older Age Adults -- 18.1.3 Older Age and Cardiovascular Disease in CoViD19 -- 18.2 CoViD19 Biomarkers in Older Adults -- 18.3 Risk Mechanisms in Older Age and CoViD19 -- 18.3.1 Immune Dysfunction and Inflammation -- 18.3.2 ACE2 Mechanisms -- 18.3.3 Miscellaneous Age Related Mechanisms -- 18.4 Summary -- References -- 19 Gender Disparity in CoViD19 -- 19.1 Epidemiology -- 19.2 Discrepancies in the Epidemiological Data -- 19.3 Factors Associated with Gender Dichotomy -- 19.4 Gender Disparity in Immune Response -- 19.5 Gender Disparity in ACE2 Mechanisms -- 19.6 Gender Disparity in Cardiovascular Diseases -- 19.6.1 Cardiovascular Pathogenetic Features and Gender -- 19.7 Summary -- References -- 20 An Overview of Quality of Research in COVID19 -- 20.1 Introduction -- 20.2 Quality Issues in CoViD19 Research and Improvement Initiatives -- 20.3 Summary -- References -- Index. |
| Record Nr. | UNINA-9910544850603321 |
|
Mallick Umair
|
||
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cardiovascular Complications of COVID-19 : Acute and Long-Term Impacts / / edited by Maciej Banach
| Cardiovascular Complications of COVID-19 : Acute and Long-Term Impacts / / edited by Maciej Banach |
| Edizione | [1st ed. 2022.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Humana, , 2022 |
| Descrizione fisica | 1 online resource (434 pages) |
| Disciplina |
616.980214
614.592414 |
| Collana | Contemporary Cardiology |
| Soggetto topico | Cardiology |
| ISBN |
9783031154782
9783031154775 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part I: Introduction -- Biology of SARS-CoV-2 coronavirus; origin, structure, and variants -- Epidemiology of COVID-19 -- Clinical symptoms and course of COVID-19 -- Risk factors of developing COVID-19 and its severe course -- Prognosis in COVID-19 patients - statistics, risk factors -- Part II: Cardiovascular Implications of the Acute Phase of COVID-19 -- Myocardial injury in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment) -- Acute coronary syndrome – destabilization of atherosclerotic plaque in COVID-19 (epidemiology, influence on prognosis, pathogen-esis and treatment) -- Acute Vascular Injury in COVID-19 -- Heart failure and acute circulatory failure in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment) -- Cardiomyopathy in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment) -- Arrhythmias in COVID-19 -- Thromboembolic events in COVID-19 -- Stroke in COVID-19 -- Pulmonary embolism after COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment) -- Interaction of anti-COVID-19 drugs with cardiovascular therapy -- Part III: Influence of the Treatment of Cardiovascular Diseases on the Course of COVID-19 -- Beyond the vaccines-Bioactive lipids in COVID-19 -- Statins and COVID-19 (mechanism of action, effect on prognosis) -- Covid-19 And Antihypertensive Treatment -- Colchicine in COVID-19 (mechanism of action, effect on prognosis) -- Antiplatelet drugs in COVID-19: mechanism of action and effect on prognosis -- Antidiabetic drugs in COVID-19 -- Part IV: Cardiovascular Complications of Long-COVID-19 -- Long COVID-19 - Definition, Epidemiology, and Clinical Implications -- Cardiovascular complications of long COVID-19 - prevalence, diagnosis and risk factors -- Cardiovascular complications of Long-COVID – management -- Part V The impact of COVID-19 pandemic on the e-services and digital tools development in medicine -- The impact of the COVID-19 pandemic on e-services and digital tools development in medicine. |
| Record Nr. | UNINA-9910637709603321 |
| Cham : , : Springer International Publishing : , : Imprint : Humana, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Central Asia and the Covid-19 Pandemic / / edited by Jean-François Caron, Hélène Thibault
| Central Asia and the Covid-19 Pandemic / / edited by Jean-François Caron, Hélène Thibault |
| Edizione | [1st ed. 2022.] |
| Pubbl/distr/stampa | Singapore : , : Springer Nature Singapore : , : Imprint : Palgrave Macmillan, , 2022 |
| Descrizione fisica | 1 online resource (185 pages) |
| Disciplina | 614.592414 |
| Collana | The Steppe and Beyond: Studies on Central Asia |
| Soggetto topico |
Asia - Politics and government
Asia - Economic conditions Public health Asian Politics Asian Economics Public Health |
| ISBN |
9789811675867
9811675864 9789811675850 9811675856 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Uyat or the Culture of Shame as a Vector of Covid-19 Contamination in Kazakhstan -- 2. Understanding the impact of misinformation on psychological state of Uzbekistani citizens during the COVID-19 outbreak -- 3. The "Sick Man of Asia": Exploring Popular Perceptions of China in Kyrgyzstan -- 4. Anti-Chinese Sentiment, the BRI, and COVID-19: Kazakh Perceptions of China in Central Asia -- 5. A Frontier Market in the COVID-19 Era: Kazakhstan's Economic Diversification in the 2020s -- 6. Kyrgyz parliamentary elections as a trigger - how COVID-19 unveiled the deep-rooted structural problems at stake. |
| Record Nr. | UNINA-9910743244403321 |
| Singapore : , : Springer Nature Singapore : , : Imprint : Palgrave Macmillan, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Colonialism and the COVID-19 pandemic : perspectives from Indigenous psychology / / Arthur W. Blume
| Colonialism and the COVID-19 pandemic : perspectives from Indigenous psychology / / Arthur W. Blume |
| Autore | Blume Arthur W. |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (248 pages) |
| Disciplina | 614.592414 |
| Collana | International and cultural psychology |
| Soggetto topico |
COVID-19 Pandemic, 2020- - Psychological aspects
Pandèmia de COVID-19, 2020- Aspectes psicològics |
| Soggetto genere / forma | Llibres electrònics |
| ISBN |
9783030928254
9783030928247 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910523774403321 |
|
Blume Arthur W.
|
||
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Computational epidemiology : data-driven modeling of COVID-19 / / Ellen Kuhl
| Computational epidemiology : data-driven modeling of COVID-19 / / Ellen Kuhl |
| Autore | Kuhl Ellen <1971-> |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (315 pages) |
| Disciplina | 614.592414 |
| Soggetto topico |
Mathematical models
Bioinformatics |
| ISBN | 3-030-82890-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910502645703321 |
|
Kuhl Ellen <1971->
|
||
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Contactless healthcare facilitation and commodity delivery management during COVID 19 pandemic / / edited by Mousmi Ajay Chaurasia and Stefan Mozar
| Contactless healthcare facilitation and commodity delivery management during COVID 19 pandemic / / edited by Mousmi Ajay Chaurasia and Stefan Mozar |
| Pubbl/distr/stampa | Gateway East, Singapore : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (165 pages) |
| Disciplina | 614.592414 |
| Collana | Advanced Technologies and Societal Change |
| Soggetto topico |
Artificial intelligence
Medicine, Preventive Computational intelligence |
| ISBN |
981-16-5411-5
981-16-5410-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910743251103321 |
| Gateway East, Singapore : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
